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Propofol is very rarely associated with seizure like phenomena (SLP), despite widespread 
use for anaesthesia and sedation. This case report describes a young lady with prolonged 
SLP lasting for more than 4 weeks after a single dose of propofol. The underlying 
pathophysiology of this condition is poorly understood but a psychological component 














Prolonged myoclonus after a single bolus dose of propofol 
Introduction 
Propofol is indicated for both induction and maintenance of general anaesthesia in adult 
and paediatric patients. It is commonly used for Intensive Care Unit (ICU) and procedural 
sedation. Although it has also been employed as an anticonvulsant, there have been 
reports of seizure-like phenomena (SLP) associated with the administration of propofol.  
This neurological side effect was usually short lived but in some patients it lasted for 
weeks and there is still no conclusion on the safety of propofol in patients with epilepsy.  
This case report describes a young lady with good past health and without any 
pre-existing neurological illness who developed prolonged myoclonus after one single 
bolus dose of propofol used for general anaesthesia in a minor operation.   
 
CASE HISTORY 
This patient was a healthy 50 kg (normal body mass index), 28-year-old Chinese woman, 
who had undergone a left knee arthroscopy.  She had been taking herbal medication 
which contained cassia obtusifolia, plantain seed, alisma orientale and semen pharbitidis 
for weight control during the 2 weeks prior to surgery, otherwise she had not consumed 
any other drugs. She had undergone general anaesthesia on one previous occasion and 
this was apparently uneventful, although her medical records were not available. This 
time anaesthesia was induced with 150 mg of propofol (Diprivan 1% ®) and 50 mcg of 
fentanyl, 5 mg of cis-atracurium was given to facilitate intubation and anaesthesia was 
maintained for 30 minutes with sevoflurane and 66% nitrous oxide in oxygen.  
Ondansetron 4 mg was given as prophylaxis against nausea and vomiting. 
 
Anaesthesia and surgery were uneventful.  No muscle relaxant reversal agent was given 
after the operation.  Extubation was smooth and she was transferred to the recovery 
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room for observation.  The patient was slightly drowsy and she had no nausea, vomiting 
or pain.  Fifteen minutes later, when a nurse replaced a blood pressure cuff on her arm, 
the patient suddenly developed violent repetitive myoclonic-dystonic shaking of all 4 
limbs.  She remained conscious throughout.   
 
The anaesthetist was called back to attend the patient and gave her 2 mg of intravenous 
midazolam and the twitching stopped. A provisional diagnosis of epilepsy was made and 
she was transferred to a general ward for observation.  Computer tomography of the 
brain, and blood test results were all negative.  As she had no further episodes, she was 
discharged home the following morning. 
 
She felt tired at home and the twitching recurred without any provocation. It lasted 2 
minutes and stopped spontaneously.  Her family immediately took her to their local 
hospital Accident and Emergency department for medical attention and she was admitted 
to a medical ward.   
 
The twitching attack was in the form of myoclonic jerky movements, mainly involving 
all 4 limbs and truncal muscles with sustained back arching.  They increased in 
frequency and she required repeated doses of intravenous midazolam to control them.  
The movements usually lasted less than 1 minute, with one to two attacks every hour.  
The doctors in the ward gave her 2 mg midazolam whenever the attacks occurred but it 
did not improve the condition.  The patient became more tired but was still arousable 
and remained conscious throughout the attacks.  She had transient apnoea for 15-45 
seconds after every twitching spell and the lowest oxygen saturation measured was 90% 
breathing room air.   An electroencephalogram (EEG) was normal and a neurologist 
diagnosed her as having opisthotonus and myoclonus.  There were 20 to 30 attacks of 
myoclonus and opisthotonus per day, with less frequency when the patient was asleep.  
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The Poison Information Centre was consulted about her herbal medication.  Cassia 
obtusifolia is laxative; plantain seed, alisma orientale and semen pharbitidis are diuretics.  
There are no known neurological effects from these herbs. 
 
As she had received repeated boluses of midazolam, she was transferred to ICU for 
observation. The patient was frightened and repeatedly asked why the shaking would not 
stop.  She became less anxious after an infusion of midazolam was commenced, but the 
involuntary myoclonic-dystonic motor movement persisted for the next 24 hr.  Since 
midazolam was ineffective, she was commenced on oral clonazepam with intermittent 
bolus injections of midazolam on patient demand but she did not improve.  On one 
occasion, all medications were stopped, and the myoclonic spells increased the following 
day.  This was suspected to be a withdrawal effect from benzodiazepines so clonazepam 
0.5 mg twice daily was resumed with a gradual tapering dose.  The myoclonus remained 
episodic and only moderately responded to treatment.    
 
The myoclonus and opisthotonus gradually improved during 2 weeks of ICU care from 
20 times to between 5 and 7 times per day.  She was transferred back to the medical 
ward on day 13.  She was bad tempered, frequently quarrelled with the attending medical 
staff and refused a psychiatric assessment.  
 
During the first week of treatment in ICU, it was noticed that physical distraction could 
alleviate the severity of myoclonus.  During the attack, sometimes the severity of her 
twitching would lessen when she was asked to pay attention to particular 
subjects.  Around the second week of ICU care, 0.9% saline was deliberately injected 
instead of midazolam and produced the same pharmacodynamic effect; the myoclonus 
stopped and the patient requested another dose during the next attack.  This placebo 
effect was later discovered by the patient when she read her medication record and she 
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became very angry as a result. She was also aware that being cold could trigger the attack 
so she deliberately removed all her bed covers to cool herself on the day of her EEG 
recording.  She explained that this would induce more myoclonus for the neurologist to 
analyse.  She felt that she could switch the myoclonus "ON and OFF". 
 
Fortunately, the condition eventually resolved spontaneously after a period of about 1 
month. The patient's myoclonic spell lasted for 27 days in total.  During this period, she 
stayed in hospital for observation.  The attacks improved to 1 to 2 times per week 
without trigger.  During this period, she was in rehabilitation with occasional 
physiotherapy exercises; otherwise she chose to stay in bed most of time.  She continued 
with the oral clonazepam in the medical ward, under the care of neurologists.  The drug 
dosage was tapered down gradually in view of the clinical improvement.  Clinical 
psychologist assessment was done but no psychological problem identified.  She was 
discharged with a long period of work disability leave and was followed up by the 
neurologists.  The medication was stopped completely 3 months after the initial attack 
and, currently, she is well without any residual neurological disability. 
  
DISCUSSION 
Propofol (2,6 di-isoprophylphenol, Diprivan®) was commercially introduced in the 
1980s by Zeneca Pharmaceuticals.1 Its rapid onset, fast recovery time and lack of 
accumulation have made it very popular for induction and maintenance of anaesthesia as 
well as sedation.  Common side effects include local pain on injection, dose dependent 
cardiovascular and respiratory depression.2 Myoclonus, seizures and other movement 
disorders have been reported in conjunction with propofol administration but they are 
very rare.  The package insert of Diprivan® mentions that opisthotonus and other 
epileptiform movements are rare complications, occurring in less than 1 in 1,000 to 
10,000 patients.2  The manufacturer, AstraZeneca, has described these rare complications 
as "almost always self-limiting and short lived with no treatment needed”, “although in 
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various patients benzodiazepines have been given”.3  In May 1989 the Committee on 
Safety of Medicines (UK) issued a warning as a result of 268 reports of adverse reactions  
 
In 2002 a review of neurological complications associated with propofol identified 516 
reports of neurological movement disorders associated with administration.4 The 
movement disorders were described as seizure-like phenomena (SLP).  These SLPs can 
occur during induction, maintenance or emergence from anaesthesia but can occasionally 
have a delayed onset (more than 30 minutes after the end of anaesthesia or sedation) 
SLPs have at least five presentations: generalized tonic-clonic seizures (GTCS), focal 
motor seizures, events presenting as increased tonus with twitching and rhythmic 
movements not perceived as GTCS, opisthotonous and involuntary movements like 
myoclonus.4,5
 
Propofol can induce myoclonus in mice.6  The precise mechanism of SLP still remains to 
be elucidated, although various theories have been proposed:  
1. Imbalances between excitatory and inhibitory pathways in the brain.  Propofol 
desensitizes chloride channels which prevents further action of gamma amino butyric 
acid (GABA).  This results in disinhibited excitatory action in the thalamocortical 
circuits.7,8  The imbalance may occur between cortical and subcortical structures, as well 
as via decreased inhibitory output from the formatio reticularis.5
2. Toxic metabolites: after a single bolus injection, propofol is rapidly distributed from 
the central compartment and, therefore, has a very short redistribution half-life of 2–7 
min and, subsequently, a relatively short context sensitive half-life.  The terminal 
elimination half-life, however, ranges from 60 min to 3 days, which depends on sex, age, 
pre-existing illnesses, concomitant medication and the duration of administration.9 
Propofol slowly returns from poorly perfused peripheral compartments back into the 
central compartment, albeit in very low concentrations. Hence propofol persists inside the 
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body for quite a long time.  It is metabolised in the liver, forming glucuronides and 
sulphates, and these inactive conjugates are excreted by the kidneys.  It has been 
suggested that these metabolites may cause neurological complications.10
3. Propofol also contains fat and other substances. The fat emulsion by itself has been 
reported to induce high fever in septic or severely neurotraumatised patients.5
 
Paradoxically although propofol has been accused of causing seizures and movement 
disorders, it has also been used as an anticonvulsant and there is evidence that propofol 
can reduce seizure duration during electroconvulsive therapy.11 There are reports of its 
ability to successfully terminate status epilepticus.12,13 The beneficial effects of propofol 
on epilepsy may be related to its depressant effect on the central nervous system, 
involving GABA, glutamate and aspartate mechanisms.14  
 
The conflicting data concerning propofol in seizures raise questions on the safety of its 
use in patients with epilepsy.  Some argue that those case reports associating propofol 
with epilepsy had no EEG assessment or the movement disorders were wrongly 
diagnosed as seizures.4 Thus the controversy persists. 
 
In our patient, the diagnosis of SLP after propofol was made by the exclusion of other 
possible causes.  Epilepsy was unlikely as the patient remained conscious during these 
episodes with a normal EEG.  The stable haemodynamic status, normal physical 
examination and blood biochemistry results made malignant hyperthermia, serotonin 
syndrome, tetanus, central nervous system infection, electrolyte disturbance or oculogyric 
crisis very unlikely.  The other anaesthetic drugs administered to the patient were 
checked.  Nitrous oxide, fentanyl and isoflurane may cause neurological 
complications15-18 but seldom result in opisthotonus and myoclonus.  On the other hand 
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propofol has frequently been reported to cause this movement disorder.3,4,7,10,14,19 SLP 
associated with propofol remains the likely cause after ruling out other possibilities. 
 
The treatment of SLP is mainly conservative, as it is self-limiting, and no mortality has 
been reported.  Benzodiazepines and anticonvulsants are usually tried in these patients. 
Even if drugs are not successful in controlling the condition, it usually resolves 
spontaneously with the range being from a few hours to 21 days.5 Our patient had this 
attack for 4 weeks, with a poor response to pharmacological agents.  Fortunately it 
stopped gradually.  The cause of such a prolonged attack is not clear, although we think 
a psychological element played a part. The SLP was triggered by cold ambient 
temperature and the patient would deliberately remove the bed covers to trigger more 
attacks.  Patients have been reported to have attacks upon sensation stimulation. There is 
one case where a patient's myoclonus could be triggered by cold air.3 The sensory input 
triggered more excitatory activities and imbalances in the nervous system. Psychological 
elements became more prominent through the successful alleviation of SLP via 
distraction and the administration of a placebo.  It is possible that she initially had a 
bone fide physical problem but then learned how to self provoke or mimic the attacks for 
attention.  
 
To conclude, propofol neurological complications are very rare but they do occur. The 
pathophysiology of this condition is poorly understood and a psychological component 
should be considered when cases are prolonged.  
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